Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments.
Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers.
Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new drug approvals and served as project lead for Gilead’s TAF/GENVOYA development program.
With subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons, Fordyce was previously Chief Resident at NYU Bellevue and spent two years as a translational research fellow at Rockefeller University.
Fordyce currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.
How do I contact Marshall Fordyce?
Has Marshall Fordyce been buying or selling shares of Vera Therapeutics?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 614,507 shares worth more than $11,882,441.89. In the last year, insiders at the sold shares 7 times. They sold a total of 1,583,251 shares worth more than $40,544,951.98. The most recent insider tranaction occured on April, 10th when SVP Joseph R Young sold 5,714 shares worth more than $228,560.00. Insiders at Vera Therapeutics own 21.7% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 4/10/2024.
